Standout Papers
Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
2008
Mapping the Antigenic and Genetic Evolution of Influenza Virus
2004 StandoutScience
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
2010 StandoutScience
HIV rebounds from latently infected cells, rather than from continuing low-level replication
2008
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
2007 StandoutNobel
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation
2010
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
2009
Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47
2003 StandoutScience
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Switch from Efavirenz to Nevirapine Associated with Resolution of Efavirenz-Related Neuropsychiatric Adverse Events and Improvement in Lipid Profiles
2006
Adherence to HAART Regimens
2003
Management of hepatitis B
2007
The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients
2007
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
2007
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
2007
Persistent immune activation in chronic HIV infection
2013
X4 and R5 HIV-1 Have Distinct Post-entry Requirements for Uracil DNA Glycosylase during Infection of Primary Cells
2010 StandoutNobel
Cancer and the ‘other’ noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings
2012
Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir
2008
Combination of HIV‐1–Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long‐Term Nonprogression
2005
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients
2008
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
2005
Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults
2009
The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
2007
CCR5 Gene Editing of Resting CD4+ T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice
2014
Rethinking amide bond synthesis
2011 StandoutNature
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs
2010
Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy
1999
Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand
2011
Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir
2008
Compliance/adherence and care management in HIV disease
1997
HIV preferentially infects HIV-specific CD4+ T cells
2002 Nature
Inferring the historical patterns of biological evolution
1999 StandoutNature
The Survival Benefits of AIDS Treatment in the United States
2006
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
2009
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
2008
Chemokine Coreceptor Signaling in HIV-1 Infection and Pathogenesis
2009
Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy
2007
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
2012 Nature
Differences in Human Immunodeficiency Virus Care and Treatment Among Subpopulations in the United States
2013
Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)–Specific T Cell Responses in Primary HIV Infection
2003
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection #
2009
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy
2015
‘Self-Protection’ of Individual CD4+ T Cells against R5 HIV-1 Infection by the Synthesis of Anti-Viral CCR5 Ligands
2008
Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1
2005
Antiretroviral Therapy for HIV Infection
1998
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards
2012 StandoutNobel
The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists
2015
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
2009
Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis
2009
Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
2009
Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
2007
A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells
2016 StandoutNobel
Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein
1999
Antiretroviral Therapy for HIV Infection in 1998
1998
Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus
2005
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
2001 StandoutScience
Antibody neutralization and escape by HIV-1
2003 StandoutNature
The Integrase Cofactor LEDGF/p75 Associates with Iws1 and Spt6 for Postintegration Silencing of HIV-1 Gene Expression in Latently Infected Cells
2015
Association of tenofovir exposure with kidney disease risk in HIV infection
2012
Treatment for Adult HIV Infection
2006
Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy
1999
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial
2009
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
2006
Intrinsic Immunity Shapes Viral Resistance of Stem Cells
2017 StandoutNobel
An internationally generalizable risk index for mortality after one year of antiretroviral therapy
2012
Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2006
Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy
2008
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
2009
Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy
2010
Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults
2002
The end of AIDS: HIV infection as a chronic disease
2013 Standout
Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity
2005
Use of therapeutic drug monitoring in HIV disease
2008
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
2009
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women
2006
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
1999
Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients
2010
Recent developments in HIV and the kidney
2008
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
2009
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
2011 StandoutNobel
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
2007
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis
2009
Brief Report
2016
Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues
2009
Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides
2007
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
2006
A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase
2018 StandoutNobel
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
2007
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
2012
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
2009 Standout
Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?
2014
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
2005 StandoutNature
Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination
2002
The CD4 lymphocyte count and risk of clinical progression
2006
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
1995 Standout
Earlier initiation of antiretroviral therapy in treatment-na??ve patients: implications of results of treatment interruption trials
2008
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
2006
Minority Quasispecies of Drug‐Resistant HIV‐1 That Lead to Early Therapy Failure in Treatment‐Naive and ‐Adherent Patients
2008
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Cancer-related inflammation
2008 StandoutNature
Synthetic therapeutic peptides: science and market
2009
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
2002
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
2003 Standout
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
2007
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients
2008
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
2013 Standout
Comparison of a Whole-Blood Interferon γ Assay With Tuberculin Skin Testing for Detecting Latent <EMPH TYPE="ITAL">Mycobacterium tuberculosis</EMPH> Infection
2001
In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth
2016
Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Patients Who Achieve Durable Virologic Suppression: Longer Follow‐Up of an Observational Cohort Study
2003
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
2002
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication
2010
Acyclic nucleoside phosphonates: Past, present and future
2006
Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
1999
HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
2001
The multifactorial nature of HIV-1 latency
2004
Adherence to Medication
2005 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection
1999
Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095
2006
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
2008
Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads
2003
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
The Challenge of Finding a Cure for HIV Infection
2009 Science
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages
1999 StandoutNobel
Interleukin‐2 Up‐Regulates Expression of the Human Immunodeficiency Virus Fusion Coreceptor CCR5 by CD4+Lymphocytes In Vivo
2000 StandoutNobel
Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA
1999
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Progress in the Development of an HIV-1 Vaccine
1998 Science
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study
2014
Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen
2000
Timing the Ancestor of the HIV-1 Pandemic Strains
2000 Science
Identifying the Target Cell in Primary Simian Immunodeficiency Virus (SIV) Infection: Highly Activated Memory CD4+T Cells Are Rapidly Eliminated in Early SIV Infection In Vivo
2000
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
2012
Cancer statistics for Hispanics/Latinos, 2015
2015
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
2000
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
1997 Standout
Therapeutic Vaccines for Chronic Infections
2004 Science
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus
2014 StandoutNobel
Azine Activation via Silylium Catalysis
2021 StandoutNobel
An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2–Class Triple Therapy Regimen for Individuals Initiating Antiretroviral Therapy
2006
Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication
2002
HIV-1 entry inhibitors: Evading the issue
1999
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review
2009
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
1999
Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection
2010
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
Chemokine immunobiology in HIV-1 pathogenesis
1999
The Susceptibility to X4 and R5 Human Immunodeficiency Virus-1 Strains of Dendritic Cells Derived In Vitro From CD34+ Hematopoietic Progenitor Cells Is Primarily Determined by Their Maturation Stage
1999
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Early establishment of a pool of latently infected, resting CD4 + T cells during primary HIV-1 infection
1998
POPULATION BIOLOGY OF HIV-1 INFECTION: Viral and CD4+T Cell Demographics and Dynamics in Lymphatic Tissues
1999
Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+T-Cell Responses from Chronically Infected Individuals
2001 StandoutNobel
New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma
2003
Review article: long‐term safety of nucleoside and nucleotide analogues in HBV ‐monoinfected patients
2016
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
2017
Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users
2002
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8 + T cells
2010 StandoutNobel
Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy
2002 Standout
Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections
2012
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
2009
In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA
2005
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial
2008
The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine
2008 StandoutNobel
Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis
2017
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
1999 StandoutScience
Integrated microfluidic bioprocessor for single-cell gene expression analysis
2008 StandoutNobel
Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers
2000
Works of Joel E. Gallant being referenced
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
2017
The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults
2002
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients
2006
HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy
2012
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
2007
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
1999 Standout
Tenofovir disoproxil fumarate (Viread®) for the treatment of HIV infection
2003
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
2006
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
2003
A Systematic Review of HIV/AIDS Survival and Delayed Diagnosis Among Hispanics in the United States
2011
Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy
2003
Antiretroviral therapy in the treatment of HIV-associated nephropathy
2006
Tenofovir Disoproxil Fumarate
2003
Changes in Renal Function Associated with Tenofovir Disoproxil Fumarate Treatment, Compared with Nucleoside Reverse‐Transcriptase Inhibitor Treatment
2005
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients
2008
Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects
2005
Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance
2003
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
2016
Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring
2006
Proliferative Responses to Human Immunodeficiency Virus Type 1 (HIV‐1) Antigens in HIV‐1–Infected Patients with Immune Reconstitution
2001
Stability of the Latent Reservoir for HIV‐1 in Patients Receiving Valproic Acid
2007
Renal function with use of a tenofovir-containing initial antiretroviral regimen
2009
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users
2001
Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine
1992
Effects of an Incentive and Education Program on Return Rates for PPD Test Reading in Patients with HIV Infection
1996
Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV Infection
2004
Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients
2011
Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
2013
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study
2005
Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies
2014
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>
2004
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients
2008
Impact of opportunistic disease on survival in patients with HIV infection
1998
Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T Cells
2006
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance
2003
Protease-inhibitor boosting in the treatment-experienced patient.
2005
When to start antiretroviral therapy: a swinging pendulum?
2008
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults
2016
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
2004
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
2016
Renal safety of tenofovir disoproxil fumarate.
2007
Antiretroviral Treatment of Adult HIV Infection
2014
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
2004
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
2016
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
2009
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
2017
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
1997 StandoutScience